Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

r oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen(TM) technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 19, 2013  The non-surgical ... temperature radiofrequency (RF) energy is effective in control ... reduces the need for medication 10 years post-procedure, ... today at the Digestive Disease Week (DDW) meeting ... . "The sustained improvement ...
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
(Date:5/19/2013)... 19, 2013 Americans live closer to ... newest American Veterinary Medical Association (AVMA) U.S. Pet Ownership ... owners consider their dog a member of the family, ... as much five years earlier. , According to the ... the national income dedicated to pets has increased every ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Passages Malibu, the leading non-12 step, holistic, and ... the launch of a “Sobriety, Health, and Wellness” survey ... “We are always looking for new ways to engage ... regarding sobriety, what’s working for people, and what isn’t,” ... Passages Addiction Treatment Centers located in Malibu and ...
(Date:5/19/2013)... 19, 2013 HealthEconomics.Com , the ... pleased to unveil a new and exciting service: HE-Xpo: ... a powerful array of real-time communication tools to expand ... and abroad. , HE-Xpo is powered by OnStream ... look and feel of being at a physical trade ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... team at Brunel University to help people ridden on wheelchair to ... a day. // ,Presently patients are asked to ... program may soon change all that. It requires only a standard ... ,This would enable doctors to build up information on ...
... The Phase II Clinical Trial conducted by a cancer institute ... for kidney cancer with the help of bevacizumab and erlotinib[1], ... effective and may help in prolonging patient's survival. ... treat, especially once it has started to spread to other ...
... a drug containing parts of diptheria toxin as a way ... //cell of patients suffering from advanced melanoma (Skin Cancer) ... trial to test the drug denileukin diftitox (also known as ... seven patients with stage IV disease experienced significant regression or ...
... Mahathir Mohamad suffered a heart attack Thursday and was admitted ... ,Mahathir, 81, had complained of mild chest pains ... Care Unit (CCU) of the National Heart Institute, the hospital ... agency. ,Mahathir had coronary artery bypass surgery in ...
... software used by doctors, AMA President, Dr Mukesh Haikerwal, ... software packages is expanding rapidly in Australia but the ... of standardised testing of clinical software may create potential ... is calling for a national regulatory framework to standardise ...
... novel method of measuring the risk of heart disease, ... their level of affluence, which also contributes to heart ... often eliminated while studying the risk factors and now ... the inclusion of new parameters, to decide the patients ...
Cached Medicine News:Health News:Pain Tracked By 3D Computer Map 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells 2
Phaco Chopper, double ended; a combination of a modified MicroFinger and a pointed "quick chop" tip, in titanium...
5mm from bend to tip 0.3x2.0mm Tip, Oblong 2 Sided Straight, at 45 degrees; In Titanium...
Angled 40 Degrees, 0.6x0.8 Elliptical Tip; in Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
Medicine Products: